Maravai Lifesciences Holdings (MRVI) Total Non-Current Liabilities (2020 - 2026)

Maravai Lifesciences Holdings' Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $308.1 million for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities fell 20.09% year-over-year to $308.1 million in Q1 2026; TTM through Mar 2026 was $308.1 million, a 20.09% decrease from a year earlier, with the FY2025 full-year figure at $361.4 million, down 4.54% from the prior year.
• Total Non-Current Liabilities retreated to $308.1 million in Q1 2026 per MRVI's latest filing, from $361.4 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $1.4 billion in Q4 2022 and bottomed at $308.1 million in Q1 2026.
• The 5-year median for Total Non-Current Liabilities is $617.2 million (2024), against an average of $825.2 million.
• Across the five-year window, Total Non-Current Liabilities climbed 16.03% in 2022 and tumbled 54.87% in 2024, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $1.4 billion in 2022, then slumped by 53.33% to $638.1 million in 2023, then plunged by 40.67% to $378.6 million in 2024, then retreated by 4.54% to $361.4 million in 2025, then decreased by 14.76% to $308.1 million in 2026.
• Per Business Quant, the three latest MRVI Total Non-Current Liabilities figures stand at $308.1 million (Q1 2026), $361.4 million (Q4 2025), and $379.4 million (Q3 2025).